fig6

Figure 6. Antitumor effect of the combination of TRAIL and obatoclax in the in vivo CAM model. SW1573 tumors were treated in the CAM model from EDD 13 to EDD 17 with TRAIL at 500 ng/mL, 500 nM obatoclax, or the combination. Values are means ± SEM of 11-12 eggs. Tumor size in the TRAIL-obatoclax group was significantly reduced compared to the control and single-agent treatment groups (P < 0.001 for all comparisons; Student’s t-test for unpaired samples).